Tikehau Capital SCA (0RP0)
London Exchange · UK · prices in EUR · close of 21 Oct 2026
Key indicators
| Last close | EUR 16.82 |
|---|---|
| 52-week range | 13.99 – 19.07 |
| Return, 1 month / 3 months | +0.4% / −2.2% |
| Return, 1 year / 3 years | −3.6% / −14.4% |
| Trend | Uptrend |
| RSI (14) | 59 |
| Volatility (1 year) | 31.1% |
| Worst drawdown (1 year) | -20.2% |
| Average daily value traded | 0.03M EUR |
| Dividend yield | 4.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Tikehau Capital is a French alternative asset management and investment firm based in Paris. It manages funds and investment strategies across private debt, private equity, real assets and capital markets, serving institutional investors, companies and individual clients. The firm also invests its own capital alongside the funds it manages, and it operates through offices in several countries. Its business centres on long-term partnership with investors seeking access to private markets.
On this site Tikehau Capital SCA appears as a stock on the London Exchange (UK), code 0RP0, with prices in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Tikehau Capital SCA (0RP0) trades on the London Exchange in UK. It last closed at EUR 16.82 on 21 October 2026.
Its price-based Market X-Ray is 50 out of 100 (a fair price profile), ranking 2,048 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 3.6% and over the last three months it fell 2.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 52 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 0.9% | ||
| From 52-week high | -11.2% | ||
| Momentum | 45 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -2.2% | ||
| 6-month return | 2.9% | ||
| 12-month return, skipping the last month | -3.9% | ||
| Stability (higher is calmer) | 66 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -20.2% | ||
| Liquidity | 21 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 63 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.8% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +6.7% |
|---|---|
| 1 month | +0.4% |
| 3 months | −2.2% |
| 6 months | +2.9% |
| 1 year | −3.6% |
| 3 years | −14.4% |
| 5 years | – |
Signals
| 50-day / 200-day average | 16.55 / 16.67 |
|---|---|
| Golden / death cross (60 days) | Death, 5 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.30 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 1 May 2026 | EUR 0.8000 |
| 2 May 2025 | EUR 0.8000 |
| 9 May 2024 | EUR 0.7500 |
| 18 May 2023 | EUR 0.7000 |
| 20 May 2022 | EUR 0.6000 |
| 21 May 2021 | EUR 0.5000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.